Drugs / Vibostolimab
Vibostolimab
also known as
MK-7684 · TIGIT INHIBITOR MK-7684 · TIGIT-TARGETING AGENT MK-7684 · Vibostolimab component of mk-7684a
Monoclonal antibody targets TIGIT via inhibition
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02964013 | Dec 2016 → Jul 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06395090 | Jan 2025 → Jun 2029 | metastatic neoplasm | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04303169 | Jun 2020 → Sep 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05005442 | Sep 2021 → Dec 2024 | hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05007106 | Sep 2021 → Aug 2025 | cholangiocarcinoma, endometrium neoplasm, gallbladder neoplasm, gastric neoplasm +7 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04725188 | Apr 2021 → Jan 2023 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05665595 | Jan 2023 → Mar 2024 | cutaneous melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05298423 | May 2022 → Jun 2026 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05226598 | Mar 2022 → Sep 2024 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05224141 | Mar 2022 → Jun 2024 overdue | small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04738487 | Apr 2021 → Sep 2024 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vibostolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005442 ↗ |
| Known as | MK-7684 | “Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg.” NCT04738487 ↗ |
| Known as | TIGIT INHIBITOR MK-7684 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Known as | TIGIT-TARGETING AGENT MK-7684 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Known as | Vibostolimab component of mk-7684a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Action | Inhibit | “vibostolimab (anti-TIGIT)” PMID 39775043 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT.” PMID 39230120 ↗ Sep 2024 |
| Route | Intravenous | “IV infusion” NCT04165070 ↗ |
| Target | TIGIT | “anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab” PMID 34800678 ↗ Nov 2021 |